The U.S. biomarkers market reached a valuation of USD 25.92 billion in 2024, with a projected CAGR of 15.16% from 2025 to 2034, reflecting robust growth across multiple market segments. Biomarkers are broadly categorized by type, including genomic, proteomic, and metabolomic markers, each playing a critical role in disease diagnosis, prognosis, and therapeutic monitoring. Among these, genomic biomarkers dominate the market, driven by advancements in next-generation sequencing (NGS), the rising adoption of liquid biopsies, and the increasing use of companion diagnostics in oncology. Proteomic biomarkers are also gaining tra